Evidence map›Paper›PMID 26178989›Full record

ArticleJournal of virology2015

HIV Vpu Interferes with NF-κB Activity but Not with Interferon Regulatory Factor 3.

Lara Manganaro, Elisa de Castro, Ana M Maestre, Kevin Olivieri, Adolfo García-Sastre, Ana Fernandez-Sesma, Viviana Simon

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. IL-15 regulates susceptibility of CD4Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  16. Limiting Respiratory Viral Infection by Targeting Antiviral and Immunological Functions of BST-2/Tetherin: Knowledge and Gaps.BioEssays : news and reviews in molecular, cellular and developmental biology · 2018
    Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lara ManganaroDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Elisa de CastroDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Ana M MaestreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Kevin OlivieriSanford-Burnham Medical Research Institute, La Jolla, California, USA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Ana Fernandez-SesmaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Viviana SimonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA viviana.simon@mssm.edu.
Icahn School of Medicine at Mount Sinai · USSanford Burnham Prebys Medical Discovery Institute · US

Funding

Molecular Virology and Systems Biology Screening CoreP01AI090935 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI YOUNG, JOHN A T · 2010 to 2014
$20.4M
MODULATION OF INNATE AND ADAPTIVE IMMUNITY BY DENGUE VIRUSR01AI073450 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FERNANDEZ-SESMA, ANA · 2008 to 2017
$3.3M
Cellular factors in gammaretrovirus replicationR01AI072645 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI YOUNG, JOHN A T · 2007 to 2011
$2.2M
Genomic Determinants of Intrinsic Antiviral Host DefensesR01AI089246 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SIMON, VIVIANA A · 2010 to 2014
$2.1M
NIAID NIH HHS AI089246NIAID NIH HHS AI72645NIAID NIH HHS P01 AI090935NIAID NIH HHS P01AI90935NIAID NIH HHS R01 AI072645NIAID NIH HHS R01 AI073450NIAID NIH HHS R01AI073450NIAID NIH HHS R01 AI089246
6 · The paper itself

Abstract

unlabelledThe accessory HIV protein Vpu inhibits a number of cellular pathways that trigger host innate restriction mechanisms. HIV Vpu-mediated degradation of tetherin allows efficient particle release and hampers the activation of the NF-κB pathway thereby limiting the expression of proinflammatory genes. In addition, Vpu reduces cell surface expression of several cellular molecules such as newly synthesized CD4. However, the role of HIV Vpu in regulating the type 1 interferon response to viral infection by degradation of the interferon regulatory factor 3 (IRF3) has been subject of conflicting reports. We therefore systematically investigated the expression of IRF3 in primary CD4(+) T cells and macrophages infected with HIV at different time points. In addition, we also tested the ability of Vpu to interfere with innate immune signaling pathways such as the NF-κB and the IRF3 pathways. We report here that HIV Vpu failed to degrade IRF3 in infected primary cells. Moreover, we observed that HIV NL4.3 Vpu had no effect on IRF3-dependent gene expression in reporter assays. On the other hand, HIV NL4.3 Vpu downmodulated NF-κB-dependent transcription. Mutation of two serines (positions 52 and 56) involved in the binding of NL4.3 Vpu to the βTrCP ubiquitin ligase abolishes its ability to inhibit NF-κB activity. Taken together, these results suggest that HIV Vpu regulates antiviral innate response in primary human cells by acting specifically on the NF-κB pathway. IMPORTANCE: HIV Vpu plays a pivotal role in enhancing HIV infection by counteraction of Tetherin. However, Vpu also regulates host response to HIV infection by hampering the type 1 interferon response. The molecular mechanism by which Vpu inhibits the interferon response is still controversial. Here we report that Vpu affects interferon expression by inhibiting NF-κB activity without affecting IRF3 levels or activity. These data suggest that Vpu facilitates HIV infection by regulating NF-κB transcription to levels sufficient for viral transcription while limiting cellular responses to infection.

Indexed as

CD4-Positive T-LymphocytesDNA PrimersFlow CytometryGene Expression RegulationGreen Fluorescent ProteinsHEK293 CellsHIV-1Human Immunodeficiency Virus ProteinsHumansImmunoblottingInterferon Regulatory Factor-3LuciferasesNF-kappa BPlasmidsSignal TransductionViral Regulatory and Accessory ProteinsDNA PrimersGreen Fluorescent ProteinsHuman Immunodeficiency Virus ProteinsInterferon Regulatory Factor-3LuciferasesNF-kappa BViral Regulatory and Accessory ProteinsViroporin Proteinsvpu protein, Human immunodeficiency virus 1

Identifiers

PMID26178989
PMCPMC4577919
OpenAlexW1875038581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.